Cargando…

Targeting NF-κB Signaling for Multiple Myeloma

Multiple myeloma (MM) is the second most common hematologic malignancy in the world. Even though survival rates have significantly risen over the past years, MM remains incurable, and is also far from reaching the point of being managed as a chronic disease. This paper reviews the evolution of MM th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Ada Hang-Heng, Shin, Eun Myoung, Tergaonkar, Vinay, Chng, Wee-Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463546/ https://www.ncbi.nlm.nih.gov/pubmed/32781681 http://dx.doi.org/10.3390/cancers12082203

Ejemplares similares

NFκB drives TERT promoter reactivation in cancer
por: Tergaonkar, Vinay
Publicado: (2015)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

Small Molecule NF-κB Pathway Inhibitors in Clinic
por: Ramadass, Venkataramanan, et al.
Publicado: (2020)

Rho protein GTPases and their interactions with NFκB: crossroads of inflammation and matrix biology
por: Tong, Louis, et al.
Publicado: (2014)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model
por: Siveen, Kodappully Sivaraman, et al.
Publicado: (2013)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

The NF-κB Activating Pathways in Multiple Myeloma
por: Roy, Payel, et al.
Publicado: (2018)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

PPFIBP1 activates NF-κB signaling to enhance chemoresistance of multiple myeloma
por: Deng, Yi, et al.
Publicado: (2023)

Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression
por: Puar, Yu Rou, et al.
Publicado: (2018)

Role of NF-κB Signaling in the Interplay between Multiple Myeloma and Mesenchymal Stromal Cells
por: Cippitelli, Marco, et al.
Publicado: (2023)

Targeting the Non-Canonical NF-κB Pathway in Chronic Lymphocytic Leukemia and Multiple Myeloma
por: Burley, Thomas A., et al.
Publicado: (2022)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
por: Xiong, Sinan, et al.
Publicado: (2021)

Drug Inhibition Profile Prediction for NFκB Pathway in Multiple Myeloma
por: Peng, Huiming, et al.
Publicado: (2011)

Genomic characterization of functional high-risk multiple myeloma patients
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2022)

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

Study on Tim3 Regulation of Multiple Myeloma Cell Proliferation via NF-κB Signal Pathways
por: Liu, Zhaoyun, et al.
Publicado: (2020)

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

NF-κB signaling in inflammation
por: Liu, Ting, et al.
Publicado: (2017)

NAIL: an evolutionarily conserved lncRNA essential for licensing coordinated activation of p38 and NFκB in colitis
por: Akıncılar, Semih Can, et al.
Publicado: (2021)

Inhibition of VCP modulates NF-κB signaling pathway to suppress multiple myeloma cell proliferation and osteoclast differentiation
por: Wei, Rongfang, et al.
Publicado: (2023)

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact
por: Li, Zhenhai, et al.
Publicado: (2019)

RNA helicase DP103 and TAK1: a new connection in cancer
por: Shin, Eun Myoung, et al.
Publicado: (2015)

NF-κB promotes the stem-like properties of leukemia cells by activation of LIN28B
por: Zhou, Jianbiao, et al.
Publicado: (2018)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
por: Teoh, Phaik Ju, et al.
Publicado: (2016)

KSP inhibitor SB743921 induces death of multiple myeloma cells via inhibition of the NF-κB signaling pathway
por: Song, In-Sung, et al.
Publicado: (2015)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
por: Lim, Su Lin, et al.
Publicado: (2019)

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination
por: Li, Zhenhai, et al.
Publicado: (2020)

Natural History and Prognostic Factors at First Relapse in Multiple Myeloma
por: Wang, Chen, et al.
Publicado: (2020)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_grbb9k20gqvrng10djj9u6k5sp